1477 logo

Ocumension Therapeutics SZSC:1477 Stock Report

Last Price

HK$4.41

Market Cap

HK$3.6b

7D

-5.0%

1Y

-34.7%

Updated

25 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Ocumension Therapeutics Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ocumension Therapeutics
Historical stock prices
Current Share PriceHK$4.41
52 Week HighHK$7.54
52 Week LowHK$4.13
Beta0.80
1 Month Change-20.68%
3 Month Change-17.26%
1 Year Change-34.67%
3 Year Change-73.75%
5 Year Changen/a
Change since IPO-80.70%

Recent News & Updates

Recent updates

Shareholder Returns

1477HK PharmaceuticalsHK Market
7D-5.0%2.0%2.3%
1Y-34.7%-2.6%22.4%

Return vs Industry: 1477 underperformed the Hong Kong Pharmaceuticals industry which returned -2.6% over the past year.

Return vs Market: 1477 underperformed the Hong Kong Market which returned 22.4% over the past year.

Price Volatility

Is 1477's price volatile compared to industry and market?
1477 volatility
1477 Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.5%
10% least volatile stocks in HK Market4.0%

Stable Share Price: 1477 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1477's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017477Victor Liuwww.ocumension.com

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.

Ocumension Therapeutics Fundamentals Summary

How do Ocumension Therapeutics's earnings and revenue compare to its market cap?
1477 fundamental statistics
Market capHK$3.60b
Earnings (TTM)-HK$343.46m
Revenue (TTM)HK$330.23m

10.9x

P/S Ratio

-10.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1477 income statement (TTM)
RevenueCN¥310.29m
Cost of RevenueCN¥129.44m
Gross ProfitCN¥180.86m
Other ExpensesCN¥503.58m
Earnings-CN¥322.73m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin58.29%
Net Profit Margin-104.01%
Debt/Equity Ratio0%

How did 1477 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 20:12
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocumension Therapeutics is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yanyin ZhuChina International Capital Corporation Limited
Fang QuanChina International Capital Corporation Limited
Ziyi ChenGoldman Sachs